Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795037 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
A Phase 1 study of Diabetic Macular Edema, sponsored by Curacle Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT04795037: Completed Phase 1 study of Diabetic Macular Edema, sponsored by Curacle Co..
NCT04795037 is a Phase 1 study of Diabetic Macular Edema that has completed, run by Curacle Co.. The registered enrollment target is 81 participants, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04795037, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by Curacle Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
Primary Outcome
To assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CU06-1004, Single dose
- DRUG CU06-1004, Multiple doses
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2022-06-25 |
| Phase | Phase 1 |
What the finished NCT04795037 record still lists
NCT04795037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04795037 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT04795037 about?
NCT04795037 is a clinical study titled "First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers". This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
What is the current status of trial NCT04795037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2021-07-15. Estimated completion is 2022-06-25.
What conditions does trial NCT04795037 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT04795037?
The interventions under investigation include: Placebo (DRUG), CU06-1004, Single dose (DRUG), CU06-1004, Multiple doses (DRUG).
Who is sponsoring clinical trial NCT04795037?
This trial is sponsored by Curacle Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04795037 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04795037's enrollment target sits among peer trials
81 33rd of 63 higher than 31 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI